Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „also“
Suchtreffer
Begriffe & Kennungen
Arava · 4.5 · 41 these also resolved, 2 with continuation of both medicinal products and 3 after discontinuation of leflunom
Eintrag öffnenAtriance · 4.8 · In addition to the adverse reactions seen in the pivotal clinical studies, there are also data from 875 patien
Eintrag öffnenAvastin · 4.8 · Nervous system Hypertensive encephalopathy (very rare) (see also section 4.4 and disorders Hypertension in sec
Eintrag öffnenAvastin · 4.8 · There have also been less common reactions of minor mucocutaneous haemorrhage in other locations, such as ging
Eintrag öffnenAvastin · 4.8 · Tumour-associated haemorrhage was also seen rarely in other tumour types and locations, including cases of cen
Eintrag öffnenAwiqli · 4.8 · See also section 5.1.
Eintrag öffnenBeneFIX · 4.8 · There are insufficient data to provide information on inhibitor incidence in PUPs (see also section 5.1).
Eintrag öffnenBenlysta · 4.8 · 31 The majority of patients were also receiving one or more of the following concomitant treatments for SLE: c
Eintrag öffnenBenlysta · 4.8 · 7 The majority of patients were also receiving one or more of the following concomitant treatments for SLE: co
Eintrag öffnenBenlysta · 4.8 · The majority of patients were also receiving one or more of the following concomitant treatments for SLE: cort
Eintrag öffnenBeyfortus · 4.8 · Safety of nirsevimab was also evaluated in HARMONIE, a randomised open-label multicentre trial in 8 034 term a
Eintrag öffnenBeyfortus · 4.8 · Safety was also evaluated in MUSIC, an open label, uncontrolled, single dose trial in 100 immunocompromised in
Eintrag öffnenBlincyto · 4.8 · BLINCYTO has also been evaluated in paediatric patients with high-risk first relapsed B-cell precursor ALL in
Eintrag öffnenBrilique · 4.5 · No data are available on concomitant use of ticagrelor with other active substances that also are potent P-gp
Eintrag öffnenBrilique · 4.5 · No data are available on concomitant use of ticagrelor with other active substances that also are potent P-gp
Eintrag öffnenBrilique · 4.5 · No data are available on concomitant use of ticagrelor with other active substances that also are potent P-gp
Eintrag öffnenBrilique · 4.5 · Ticagrelor is primarily a CYP3A4 substrate and a mild inhibitor of CYP3A4. Ticagrelor is also a P-glycoprotein
Eintrag öffnenBrilique · 4.5 · Ticagrelor is primarily a CYP3A4 substrate and a mild inhibitor of CYP3A4. Ticagrelor is also a P-glycoprotein
Eintrag öffnenBrilique · 4.5 · Ticagrelor is primarily a CYP3A4 substrate and a mild inhibitor of CYP3A4. Ticagrelor is also a P-glycoprotein
Eintrag öffnenBriviact (in Italy: Nubriveo) · 4.5 · 26 Other enzyme inducers Other strong enzyme inducers (such as St John´s wort (Hypericum perforatum)) may also
Eintrag öffnen